D68.59 Billable / specific Other primary thrombophilia
ICD-10-CM D68.59 identifies “Other primary thrombophilia” as a billable/specific code in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Code-level instructions
Inclusion terms7
- Antithrombin III deficiency
- Hypercoagulable state NOS
- Primary hypercoagulable state NEC
- Primary thrombophilia NEC
- Protein C deficiency
- Protein S deficiency
- Thrombophilia NOS
Inherited instructions
Chapters 3 · Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
Excludes 29
- autoimmune disease (systemic) NOS (M35.9)
- certain conditions originating in the perinatal period (P00-P96)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- human immunodeficiency virus [HIV] disease (B20)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
D68 · Other coagulation defects
Excludes 11
abnormal coagulation profile NOS (R79.1)
D68.5 · Primary thrombophilia
Inclusion terms1
Primary hypercoagulable states
Excludes 19
- antiphospholipid syndrome (D68.61)
- lupus anticoagulant (D68.62)
- secondary activated protein C resistance (D68.69)
- secondary antiphospholipid antibody syndrome (D68.69)
- secondary lupus anticoagulant with hypercoagulable state (D68.69)
- secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69)
- systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
- systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312)
- thrombotic thrombocytopenic purpura (M31.19)
Official index references
Official index references (11)
Deficiency, deficient (3)
- Deficiency, deficient › antithrombin(antithrombin III)Disease index
- Deficiency, deficient › protein › CDisease index
- Deficiency, deficient › protein › SDisease index
Hypercoagulable(state) (5)
- Hypercoagulable(state)Disease index
- Hypercoagulable(state) › antithrombin(III) deficiencyDisease index
- Hypercoagulable(state) › primary NECDisease index
- Hypercoagulable(state) › protein C deficiencyDisease index
- Hypercoagulable(state) › protein S deficiencyDisease index
Hypercoagulation(state) (1)
- Hypercoagulation(state)Disease index
Thrombophilia (2)
- ThrombophiliaDisease index
- Thrombophilia › primary NECDisease index
History
Code history
Latest recorded change · FY2023
ChangedUnchanged
FY2023
Effective from
- Inherited rules changed
Other primary thrombophilia
Billable diagnosis code
CDC/NCHS · FY2023All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | Inherited rules changed |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | Inherited rules changed |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Historical ICD-9 mappings · 2018
Historical mapping only; not an automatic code substitution.
- 289.81 · Approximate
This entry is a complete code in the selected edition. Reference checks do not establish clinical appropriateness or guarantee reimbursement.